Julie Mori

2.2k total citations · 1 hit paper
25 papers, 1.7k citations indexed

About

Julie Mori is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Julie Mori has authored 25 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 9 papers in Virology and 9 papers in Epidemiology. Recurrent topics in Julie Mori's work include HIV Research and Treatment (9 papers), Parvovirus B19 Infection Studies (7 papers) and HIV/AIDS drug development and treatment (7 papers). Julie Mori is often cited by papers focused on HIV Research and Treatment (9 papers), Parvovirus B19 Infection Studies (7 papers) and HIV/AIDS drug development and treatment (7 papers). Julie Mori collaborates with scholars based in United Kingdom, United States and Brazil. Julie Mori's co-authors include Mike Westby, Manos Perros, Caroline Smith‐Burchnell, Patrick Dorr, Anthony Wood, Malcolm Macartney, Paul Griffin, Blanda Stammen, Rob Webster and David A. Price and has published in prestigious journals such as PLoS ONE, Journal of Virology and Journal of Clinical Microbiology.

In The Last Decade

Julie Mori

24 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Patrick Dorr, Mike Westby et al. Antimicrobial Agents and Chemotherapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Mori United Kingdom	14	1.0k	948	332	317	312	25	1.7k
Ramin B. Arani United States	16	772 0.8×	1.2k 1.3×	584 1.8×	572 1.8×	438 1.4×	27	2.3k
Shawn P. O’Neil United States	23	455 0.5×	1.3k 1.3×	324 1.0×	1.2k 3.6×	529 1.7×	42	2.1k
B. Öberg Sweden	23	624 0.6×	488 0.5×	495 1.5×	175 0.6×	644 2.1×	67	1.6k
Ven Natarajan United States	26	1.2k 1.2×	1.7k 1.8×	436 1.3×	892 2.8×	531 1.7×	56	2.6k
Margarita Bofill Spain	21	510 0.5×	881 0.9×	407 1.2×	1.2k 3.8×	594 1.9×	46	2.2k
Sandra Nusinoff-Lehrman United States	12	1.1k 1.1×	907 1.0×	234 0.7×	247 0.8×	636 2.0×	14	1.8k
Kersten K. Koelsch Australia	20	1.1k 1.0×	1.3k 1.4×	223 0.7×	901 2.8×	365 1.2×	33	2.3k
M Popovic United States	29	668 0.7×	1.2k 1.2×	266 0.8×	2.0k 6.4×	416 1.3×	51	3.1k
Sajal K. Ghosh United States	17	1.7k 1.7×	2.5k 2.7×	541 1.6×	935 2.9×	638 2.0×	31	3.5k
Kurt Hertogs United States	40	3.7k 3.7×	3.5k 3.7×	568 1.7×	108 0.3×	554 1.8×	84	4.3k

Countries citing papers authored by Julie Mori

Since Specialization

Citations

This map shows the geographic impact of Julie Mori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Mori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Mori more than expected).

Fields of papers citing papers by Julie Mori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Mori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Mori. The network helps show where Julie Mori may publish in the future.

Co-authorship network of co-authors of Julie Mori

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Mori. A scholar is included among the top collaborators of Julie Mori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Mori. Julie Mori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abagge, Kerstin Taniguchi, et al.. (2025). <b>New cosmetics patch test series: A proposal</b>. Revista Alergia México. 72(2). 107–118.

Coakley, Eoin, Alaa Ahmad, Kajal Larson, et al.. (2019). LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study. Open Forum Infectious Diseases. 6(Supplement_2). S995–S995. 7 indexed citations

DeVincenzo, John P., Dereck Tait, John Efthimiou, et al.. (2019). A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein. Antimicrobial Agents and Chemotherapy. 64(2). 56 indexed citations

Lewis, Marilyn, Julie Mori, Jonathan Toma, et al.. (2018). Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials. PLoS ONE. 13(12). e0204099–e0204099. 10 indexed citations

Mori, Julie, Andrew Catchpole, Edward J. Murray, et al.. (2016). A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model. PLoS ONE. 11(12). e0166113–e0166113. 5 indexed citations

Vernazza, Pietro, Cunshan Wang, Anton Pozniak, et al.. (2013). Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 171–179. 16 indexed citations

Corbau, Romuald, Julie Mori, Chris Phillips, et al.. (2010). Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. 54(10). 4451–4463. 51 indexed citations

Westby, Mike, Caroline Smith‐Burchnell, Julie Mori, et al.. (2006). Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry. Journal of Virology. 81(5). 2359–2371. 273 indexed citations

Dorr, Patrick, Mike Westby, Paul Griffin, et al.. (2005). Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrobial Agents and Chemotherapy. 49(11). 4721–4732. 909 indexed citations breakdown →

10.

Pires, Mário Cézar, et al.. (2002). Reactivity of anti-Blomia tropicalisIgG and IgE in patients with atopic dermatitis. Clinical and Experimental Dermatology. 27(4). 309–313. 4 indexed citations

11.

Mori, Julie, et al.. (2001). Determination of Blomia tropicalis‐specific IgE and IgG subclasses in atopic dermatitis patients. Allergy. 56(2). 180–184. 17 indexed citations

12.

Cohen, B J, A. M. Field, Julie Mori, et al.. (1995). Morphology and antigenicity of recombinant B19 parvovirus capsids expressed in transfected COS-7 cells. Journal of General Virology. 76(5). 1233–1237. 5 indexed citations

13.

Mori, Julie & Jonathan P. Clewley. (1994). Polymerase chain reaction and sequencing for typing rhinovirus RNA. Journal of Medical Virology. 44(4). 323–329. 37 indexed citations

14.

Mori, Julie, et al.. (1993). Detection of HIV-1 in serum, using reverse transcription and the polymerase chain reaction (RT-PCR). Journal of Virological Methods. 43(1). 101–109. 9 indexed citations

15.

Cohen, B J, Kevin Brown, Julie Mori, et al.. (1991). Detection of B19 Parvovirus in Human Fetal Tissues by Electron Microscopy. Journal of Medical Virology. 35(2). 85–95. 23 indexed citations

16.

Nascimento, Jussara Pereira do, N. Hallam, Julie Mori, et al.. (1991). Detection of B19 parvovirus in human fetal tissues by in situ hybridisation. Journal of Medical Virology. 33(2). 77–82. 21 indexed citations

17.

Brown, Kevin, Julie Mori, B J Cohen, & A. M. Field. (1991). In vitro propagation of parvovirus B19 in primary foetal liver culture. Journal of General Virology. 72(3). 741–745. 39 indexed citations

18.

Mori, Julie, et al.. (1990). Molecular approaches for production of B19 antigen.. PubMed. 14–27. 4 indexed citations

19.

Mori, Julie, A. M. Field, J P Clewley, & B J Cohen. (1989). Dot blot hybridization assay of B19 virus DNA in clinical specimens. Journal of Clinical Microbiology. 27(3). 459–464. 55 indexed citations

20.

Mori, Julie, Paula Beattie, David W. Melton, B J Cohen, & Jonathan P. Clewley. (1987). Structure and Mapping of the DNA of Human Parvovirus B19. Journal of General Virology. 68(11). 2797–2806. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact